COVID-19 trials registries data warehouse

 Return to trial list

Trial - EUCTR2020-001722-66-ES


Column Value
Trial registration number EUCTR2020-001722-66-ES
Full text link
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

First author
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Clinical Trial Unit - CTU

Contact
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

acruceta@clinic.cat

Registration date
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

2020-04-27

Recruitment status
Last imported at : Sept. 19, 2023, 4:13 p.m.
Source : EU Clinical Trials Register

Terminated

Study design
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

RCT

Allocation
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Randomized

Design
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Parallel

Masking
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Open label

Center
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

multi-center

Study aim
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Treatment

Inclusion criteria
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

1-Age 18-79 years, 2-Diagnosis of COVID-19 by PCR in nasopharyngeal, sputum or bronchial aspirate smears : 3-Admission to ICU with invasive mechanical ventilation, 4-Telephone informed consent granted by family members or legal representative. 1-Edad 18-79 años, 2-Diagnóstico de enfermedad COVID-19 por PCR en frotis nasofaringeo, esputo o broncoaspirado 3, 3-Ingreso en UCI con ventilación mecánica invasiva, 4-Consentimiento informado telefónico otorgado por familiares o representante legal.

Exclusion criteria
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

1-> 7 days of invasive mechanical ventilation, 2- Refractory shock (norepinephrine> 0.5 microg / Kg / min), 3- Decompensated liver cirrhosis 4- Chronic hemodialysis 5- Active neoplastic disease 6- Moderate or severe heart failure (NYHA III- IV), 7- Moderate-severe lung disease (GOLD III-IV), 8- HIV with AIDS criteria. 1- > 7 días de ventilación mecánica invasiva, 2- Shock refractario (noradrenalina > 0.5 microg/Kg/min), 3- Cirrosis hepática descompensada 4- Hemodiálisis crónica 5- Enfermedad neoplásica activa 6- Insuficiencia cardiaca moderada o grave (NYHA III-IV), 7- Enfermedad pulmonar moderada-grave (GOLD III-IV), 8- VIH con criterios SIDA.

Number of arms
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

2

Funding
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Fundació Clínic per a la recerca Biomèdica

Inclusion age min
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

18

Inclusion age max
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

79

Countries
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Spain

Type of patients
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Critical disease at enrollment

Severity scale
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

8: Critical disease at enrollment

Total sample size
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

116

primary outcome
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Impact of plasma exchange on the rate and probability of survival 28 days after inclusion. Impacto del recambio plasmático sobre la tasa y probabilidad de supervivencia a los 28 días de la inclusión

Notes
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

nan

Phase
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Phase 2

Arms
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

[{"arm_notes": "", "treatment_id": 588, "treatment_name": "Human albumin serum", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 600, "treatment_name": "Human normal albumin", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}]